Cargando…

Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation

Gastroretentive tablets of propranolol hydrochloride were developed by direct compression method using citric acid and sodium bicarbonate as the effervescent base. Hydroxypropyl methylcellulose; HPMC K15M was used to prepare the floating tablets to retard the drug release for 12h in stomach. Na-carb...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaturvedi, Kiran, Umadevi, S., Vaghani, Subhash
Formato: Texto
Lenguaje:English
Publicado: Österreichische Apotheker-Verlagsgesellschaft 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007615/
https://www.ncbi.nlm.nih.gov/pubmed/21179326
http://dx.doi.org/10.3797/scipharm.0909-02
_version_ 1782194397330276352
author Chaturvedi, Kiran
Umadevi, S.
Vaghani, Subhash
author_facet Chaturvedi, Kiran
Umadevi, S.
Vaghani, Subhash
author_sort Chaturvedi, Kiran
collection PubMed
description Gastroretentive tablets of propranolol hydrochloride were developed by direct compression method using citric acid and sodium bicarbonate as the effervescent base. Hydroxypropyl methylcellulose; HPMC K15M was used to prepare the floating tablets to retard the drug release for 12h in stomach. Na-carboxymethyl cellulose (NaCMC) or carbopol 934P was added to alter the drug release profile or the dimensional stability of the formulation. Dicalcium phosphate (DCP) was used as filler. Formulations were evaluated for floating lag time, duration of floating, dimensional stability, drug content and in vitro drug release profile. The formulations were found to have floating lag time less than 1min. It was found that the dimensional stability of the formulations increase with increasing concentration of the swelling agent. The release mechanism of propranolol hydrochloride from floating tablets was evaluated on the basis of Peppas and Higuchi model. The ‘n’ value of the formulations ranged from 0.5201 to 0.7367 (0.5<n<1.0) which indicated anomalous (non-Fickian) transport mechanism. Formulation containing 27.5% HPMC K15M, 29% DCP, 3.75% citric acid and 18.75% sodium bicarbonate seemed most desirable. FTIR, DSC and XRPD studies indicated the absence of any significant chemical interaction within dug and excipients. Stability study of optimized formulation revealed no significant change and found to be stable.
format Text
id pubmed-3007615
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Österreichische Apotheker-Verlagsgesellschaft
record_format MEDLINE/PubMed
spelling pubmed-30076152010-12-22 Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation Chaturvedi, Kiran Umadevi, S. Vaghani, Subhash Sci Pharm Original Papers Gastroretentive tablets of propranolol hydrochloride were developed by direct compression method using citric acid and sodium bicarbonate as the effervescent base. Hydroxypropyl methylcellulose; HPMC K15M was used to prepare the floating tablets to retard the drug release for 12h in stomach. Na-carboxymethyl cellulose (NaCMC) or carbopol 934P was added to alter the drug release profile or the dimensional stability of the formulation. Dicalcium phosphate (DCP) was used as filler. Formulations were evaluated for floating lag time, duration of floating, dimensional stability, drug content and in vitro drug release profile. The formulations were found to have floating lag time less than 1min. It was found that the dimensional stability of the formulations increase with increasing concentration of the swelling agent. The release mechanism of propranolol hydrochloride from floating tablets was evaluated on the basis of Peppas and Higuchi model. The ‘n’ value of the formulations ranged from 0.5201 to 0.7367 (0.5<n<1.0) which indicated anomalous (non-Fickian) transport mechanism. Formulation containing 27.5% HPMC K15M, 29% DCP, 3.75% citric acid and 18.75% sodium bicarbonate seemed most desirable. FTIR, DSC and XRPD studies indicated the absence of any significant chemical interaction within dug and excipients. Stability study of optimized formulation revealed no significant change and found to be stable. Österreichische Apotheker-Verlagsgesellschaft 2010 2010-09-26 /pmc/articles/PMC3007615/ /pubmed/21179326 http://dx.doi.org/10.3797/scipharm.0909-02 Text en © Chaturvedi et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Chaturvedi, Kiran
Umadevi, S.
Vaghani, Subhash
Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation
title Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation
title_full Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation
title_fullStr Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation
title_full_unstemmed Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation
title_short Floating Matrix Dosage Form for Propranolol Hydrochloride Based on Gas Formation Technique: Development and In Vitro Evaluation
title_sort floating matrix dosage form for propranolol hydrochloride based on gas formation technique: development and in vitro evaluation
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007615/
https://www.ncbi.nlm.nih.gov/pubmed/21179326
http://dx.doi.org/10.3797/scipharm.0909-02
work_keys_str_mv AT chaturvedikiran floatingmatrixdosageformforpropranololhydrochloridebasedongasformationtechniquedevelopmentandinvitroevaluation
AT umadevis floatingmatrixdosageformforpropranololhydrochloridebasedongasformationtechniquedevelopmentandinvitroevaluation
AT vaghanisubhash floatingmatrixdosageformforpropranololhydrochloridebasedongasformationtechniquedevelopmentandinvitroevaluation